Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/yingli-pharma-presents-a-pivotal-phase-2-study-data-evaluating-linperlisib-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-in-an-oral-session-at-the-american-society-of-hematology-2023-annual-meeting-302010879.html

PR NEWSWIRE
11 Dec 2023

https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

PRNEWSWIRE
10 Jun 2021

https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

PRNEWSWIRE
10 Jun 2021

https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

PRNEWSWIRE
10 Jun 2021

https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

PRNEWSWIRE
10 Jun 2021